On Monday, Shares of Apple Inc. (NASDAQ:AAPL), lost -0.20% to $126.92, as consumer stocks were mostly lower Monday with shares of consumer staples companies in the S&P 500 retreating 0.5% while shares of consumer discretionary firms in the S&P 500 were declining 0.4%.
Apple’s stock has the beta value of 0.87, and its volatility for the week is 1.32%, while for the month it is 1.32%. The company has the market capitalization of $731.19B. The company holds the book value per share of 22.27, whereas cash per share is 5.74. Price to book ratio remained 5.70, while price to sale ratio is 22.09. Analysts mean recommendation for the stock is said to be 2.00. (where 1=Buy, 5=sale).
Apple Inc. designs, manufactures, and markets mobile communication and media devices, personal computers, watches, and portable digital music players worldwide. The company also sells related software, services, accessories, networking solutions, and third-party digital content and applications.
Shares of The Procter & Gamble Company (NYSE:PG), declined -0.95% to $78.12, during its last trading session.
PG - Actress, recording artist and trendsetter Selena Gomez knows a thing or two about beautiful hair, from rocking intricate up-dos on the red carpet to her signature free-flowing waves on the concert stage. Now, Pantene is tapping Hollywood’s “It” Girl to be the face – and hair – for its newest campaign that celebrates the power of strong hair.
“I’ve always loved using Pantene, so it’s a dream come true to be the brand’s newest ambassador. Not only because Pantene stands for strong, healthy hair but also because it encourages women to be their best selves,” says Gomez. “My style is constantly evolving and I love to take risks, so I’m always changing my hair style. I rely on Pantene to keep my hair strong and healthy so I can take on each day with confidence.”
“Pantene has always celebrated beautiful hair and strong women,” says Jodi Allen, Vice President of Hair Care & Color for North America at Procter & Gamble. “I am proud that Selena Gomez is the newest member of the Pantene family. Her talents go beyond being an actress and singer. She is a modern beauty with amazing hair and is a true inspiration.”
The Procter & Gamble Company, together with its auxiliaries, manufactures and sells branded consumer packaged goods. The company operates through five segments: Beauty; Grooming; Health Care; Fabric Care and Home Care; and Baby, Feminine and Family Care.
Finally, CTI BioPharma Corp. (NASDAQ:CTIC), ended its last trade with 4.41% gain, and closed at $2.13.
CTI BioPharma Corp., declared findings from an investigator-sponsored Phase 2 trial in patients with either primary (de novo) acute myeloid leukemia (AML) or AML that has evolved from myelodysplastic syndrome (MDS). Results showed the combination of tosedostat with low dose cytarabine/Ara-C (LDAC) resulted in an overall response rate (ORR) of 54 percent in elderly patients with AML – with 45 percent of patients achieving durable complete responses (CR). These final results were presented by Dr. Giuseppe Visani, Director of Hematology and Stem Cell Transplant Center at AORMN, Pesaro, Italy in a poster session (abstract #P564) during the 20th Congress of the European Hematology Association (EHA), June 11-14, 2015 in Vienna, Austria.
AML is the most common acute leukemia affecting adults, and its incidence enhances with age. AML may develop from the progression of other diseases, such as MDS, which is a blood cancer that also affects the bone marrow and leads to a decrease in circulating red blood cells. Tosedostat is a potential first-in-class selective inhibitor of aminopeptidases, which are required by tumor cells to provide amino acids necessary for growth and tumor cell survival.
“Both the types and length of responses in this trial with tosedostat are very encouraging – particularly given the limited options and poor outcomes historically observed in elderly patients with acute myeloid leukemia, either de novo or secondary after myelodysplastic syndrome,” said Dr. Visani. “Importantly, through this study we have also identified potential biomarkers that may assist identify high-risk patients in which we are more likely to see these clinically meaningful results – the findings of which are quite compelling and warrant further study.”
CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
